Posted by Michael Wonder on 19 Jul 2024
Bavarian Nordic receives EMA filing acceptance and validation of the MAA for its chikungunya vaccine
18 July 2024 - EMA will now initiate its centralised review procedure under accelerated assessment for Bavarian Nordic’s chikungunya vaccine.
Bavarian Nordic today announced that the EMA has validated the marketing authorisation application, which was submitted in June 2024 for CHIKV VLP, the Company’s vaccine candidate for immunisation to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older.
